Free Trial
Michael Leuchten

Michael Leuchten Analyst Performance

Managing Director at Jefferies Financial Group

Michael Leuchten is a stock analyst at Jefferies Financial Group in the healthcare sector, covering 4 publicly traded companies. Over the past year, Michael Leuchten has issued 2 stock ratings, including and hold recommendations. While full access to Michael Leuchten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Leuchten's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
11 Last 10 Years
Buy Recommendations
45.45% 5 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy45.5%5 ratings
Hold45.5%5 ratings
Sell9.1%1 ratings

Out of 11 total stock ratings issued by Michael Leuchten at Jefferies Financial Group, the majority (45.5%) have been Buy recommendations, followed by 45.5% Hold and 9.1% Sell.

Exchange Coverage

ExchangePercentageCount
NYSE
100.0% of companies on NYSE
4 companies

Michael Leuchten, an analyst at Jefferies Financial Group, currently covers 4 companies listed on , with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
4 companies
100.0%

Michael Leuchten of Jefferies Financial Group specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
4 companies
100.0%

Michael Leuchten's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
GSK PLC Sponsored ADR stock logo
GSK
GSK
10/29/2026Downgrade$48.71$55.90Hold
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2/12/2026Upgrade$48.77$43.90Hold
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
10/27/2025Initiated Coverage$53.02Underperform
Novartis AG stock logo
NVS
Novartis
10/27/2025Reiterated Rating$130.48Hold
GSK PLC Sponsored ADR stock logo
GSK
GSK
10/27/2025Reiterated Rating$43.24Buy
AstraZeneca Plc stock logo
AZN
AstraZeneca
10/27/2025Initiated Coverage$83.29Buy